AbbVie Inc (ABBV) : J.safra Asset Management Corp reduced its stake in AbbVie Inc by 22.53% during the most recent quarter end. The investment management company now holds a total of 47,684 shares of AbbVie Inc which is valued at $2,956,408 after selling 13,870 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on May 10, 2016.AbbVie Inc makes up approximately 2.43% of J.safra Asset Management Corp’s portfolio.
Other Hedge Funds, Including , Blackrock Investment Management reduced its stake in ABBV by selling 1,501,611 shares or 23.44% in the most recent quarter. The Hedge Fund company now holds 4,905,480 shares of ABBV which is valued at $304,139,760. AbbVie Inc makes up approx 0.40% of Blackrock Investment Management’s portfolio.Sippican Capital Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 281 additional shares and now holds a total of 7,543 shares of AbbVie Inc which is valued at $467,666. AbbVie Inc makes up approx 0.60% of Sippican Capital Advisors’s portfolio.Alerus Investment Advisors Corp boosted its stake in ABBV in the latest quarter, The investment management firm added 15,273 additional shares and now holds a total of 26,958 shares of AbbVie Inc which is valued at $1,685,145. AbbVie Inc makes up approx 0.30% of Alerus Investment Advisors Corp’s portfolio. Bluecrest Capital Management Ltd added ABBV to its portfolio by purchasing 15,249 company shares during the most recent quarter which is valued at $953,215. AbbVie Inc makes up approx 0.08% of Bluecrest Capital Management Ltd’s portfolio.Tiemann Investment Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 17,404 shares of AbbVie Inc which is valued at $1,087,924. AbbVie Inc makes up approx 1.08% of Tiemann Investment Advisors’s portfolio.
AbbVie Inc opened for trading at $61.91 and hit $62.62 on the upside on Monday, eventually ending the session at $62.45, with a gain of 0.73% or 0.45 points. The heightened volatility saw the trading volume jump to 67,07,435 shares. Company has a market cap of $101,004 M.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.